FIMPX Mutual Fund Forecast & Price Targets

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

FIMPX Analyst Rating

Strong Buy

77 Buy

7 Hold

0 Sell

Based on the consensus analyst ratings on 84 stocks held in FIMPX.

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

FIMPX Analyst Price Target

Average Price Target

$39.29

Based on 84 Wall Street analysts offering 12 month price targets to Nuveen Small Cap Growth opportunities Cl I holdings in the last 3 months. The average price target is $39.29 with a high forecast of $46.31 and a low forecast of $31.92. The average price target represents a 25.13% change from the last price of $31.40.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"29":"$29","38":"$38","47":"$47","33.5":"$33.5","42.5":"$42.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":46.312,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$46.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.291,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.92,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$31.92</span>\n  </div></div>","useHTML":true}}],"tickPositions":[29,33.5,38,42.5,47],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n              \n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.42,32.565538461538466,33.711076923076924,34.85661538461539,36.002153846153846,37.14769230769231,38.29323076923077,39.43876923076923,40.58430769230769,41.729846153846154,42.87538461538461,44.020923076923076,45.16646153846153,{"y":46.312,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.42,32.02546153846154,32.630923076923075,33.236384615384615,33.841846153846156,34.44730769230769,35.05276923076923,35.65823076923077,36.26369230769231,36.86915384615384,37.47461538461538,38.080076923076916,38.68553846153846,{"y":39.291,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.42,31.458461538461542,31.49692307692308,31.53538461538462,31.573846153846155,31.612307692307695,31.65076923076923,31.68923076923077,31.72769230769231,31.76615384615385,31.804615384615385,31.843076923076925,31.88153846153846,{"y":31.92,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.85,"date":1714521600000,"info":"<div>Price: <b>$31<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":31.59,"date":1717372800000,"info":"<div>Price: <b>$32<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":31.48,"date":1719792000000,"info":"<div>Price: <b>$31<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":32.95,"date":1722470400000,"info":"<div>Price: <b>$33<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":32.71,"date":1725321600000,"info":"<div>Price: <b>$33<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":33.49,"date":1727740800000,"info":"<div>Price: <b>$33<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":34.39,"date":1730419200000,"info":"<div>Price: <b>$34<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":37.79,"date":1733097600000,"info":"<div>Price: <b>$38<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":35.55,"date":1735776000000,"info":"<div>Price: <b>$36<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":36.42,"date":1738540800000,"info":"<div>Price: <b>$36<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":32.87,"date":1740960000000,"info":"<div>Price: <b>$33<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":31.26,"date":1743465600000,"info":"<div>Price: <b>$31<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":31.42,"date":1746057600000,"info":"<div>Price: <b>$31<b/></div>","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$46.31

Average Price Target$39.29

Lowest Price Target$31.92

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

FIMPX Stocks With Highest Upside Potential

xxxxxxxxxxxxxxxxxxxxxxxxxxx

PCVX

Vaxcyte, Inc.

11 Buy

0 Hold

0 Sell

Strong Buy

$117.88

xxxxxxxxxxxxxxxxxxxxxxxxxxx

IMVT

Immunovant, Inc.

8 Buy

2 Hold

0 Sell

Strong Buy

$48.00

xxxxxxxxxxxxxxxxxxxxxxxxxxx

BHVN

Biohaven Ltd.

10 Buy

0 Hold

0 Sell

Strong Buy

$62.29

xxxxxxxxxxxxxxxxxxxxxxxxxxx

CRNX

Crinetics Pharma

11 Buy

0 Hold

0 Sell

Strong Buy

$77.70

xxxxxxxxxxxxxxxxxxxxxxxxxxx

ZETA

Zeta Global Holdings Corp. Class A

11 Buy

4 Hold

0 Sell

Moderate Buy

$26.67

FIMPX Stocks With Highest Downside Potential

xxxxxxxxxxxxxxxxxxxxxxxxxxx

EVR

Evercore Partners

3 Buy

3 Hold

0 Sell

Moderate Buy

$214.83

xxxxxxxxxxxxxxxxxxxxxxxxxxx

SHAK

Shake Shack Inc

9 Buy

7 Hold

1 Sell

Moderate Buy

$110.19

xxxxxxxxxxxxxxxxxxxxxxxxxxx

RBRK

Rubrik, Inc. Class A

15 Buy

2 Hold

0 Sell

Strong Buy

$80.87

xxxxxxxxxxxxxxxxxxxxxxxxxxx

BMI

Badger Meter

5 Buy

2 Hold

0 Sell

Moderate Buy

$236.50

xxxxxxxxxxxxxxxxxxxxxxxxxxx

FROG

Jfrog Ltd.

12 Buy

2 Hold

0 Sell

Strong Buy

$43.25

FIMPX Mutual Fund FAQ

What is FIMPX’s average 12-month price target, according to analysts?

Based on analyst ratings, Nuveen Small Cap Growth opportunities Cl I’s 12-month average price target is 39.29.

What is FIMPX’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for FIMPX, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is FIMPX a Buy, Sell or Hold?

Nuveen Small Cap Growth opportunities Cl I has a consensus rating of Strong Buy which is based on 77 buy ratings, 7 hold ratings and 0 sell ratings.

What is Nuveen Small Cap Growth opportunities Cl I’s price target?

The average price target for Nuveen Small Cap Growth opportunities Cl I is 39.29. This is based on 84 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $46.31 ,the lowest forecast is $31.92. The average price target represents N/A Increase from the current price of N/A.

What do analysts say about Nuveen Small Cap Growth opportunities Cl I?

Nuveen Small Cap Growth opportunities Cl I’s analyst rating consensus is a Strong Buy. This is based on the ratings of 84 Wall Streets Analysts.

How can I buy shares of FIMPX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing